<DOC>
	<DOCNO>NCT01815736</DOCNO>
	<brief_summary>This study evaluate non-inferiority switch tenofovir alafenamide ( TAF ) -containing fix dose combination ( FDC ) relative maintain tenofovir disoproxil fumarate ( TDF ) -containing combination regimen virologically suppress HIV-infected participant determine HIV-1 RNA &lt; 50 copies/mL Week 48 .</brief_summary>
	<brief_title>Switching From TDF-Containing Combination Regimen TAF-Containing Fixed Dose Combination ( FDC ) Virologically-Suppressed , HIV-1 Positive Participants</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Key Ability understand sign write informed consent form , must obtain prior initiation study procedure Currently receive antiretroviral therapy consist E/C/F/TDF , EFV/FTC/TDF , RTV+ATV+FTC/TDF , COBI+ATV+FTC/TDF ≥ 6 consecutive month precede final visit earlier study Completion Week 144 visit study GSUS2360102 , GSUS2360103 , GSUS2160114 , completion Week 96 visit study GSUS2640110 ( participant EFVbased regimen ) , completion study GSUS2360104 , GSUS2160105 Plasma HIV1 RNA concentration undetectable level least 6 consecutive month prior screen visit HIV RNA &lt; 50 copies/mL screen visit Normal echocardiograph ( ECG ) Estimated glomerular filtration rate ( GFR ) ≥ 50 mL/min accord CockcroftGault formula creatinine clearance Hepatic transaminase ( AST ALT ) ≤ 5 × upper limit normal range ( ULN ) Direct bilirubin ≤ 1.5 x ULN Adequate hematologic function Serum amylase ≤ 5 × ULN Females childbearing potential must agree utilize highly effective contraception method nonheterosexually active practice sexual abstinence screen throughout duration study treatment 12 week follow last dose study drug receive EFV/FTC/TDF regimen , 30 day assign regimen . Female participant utilize hormonal contraceptive one birth control method must use method least three month prior study dose Female participant stop menstruate ≥ 12 month documentation ovarian hormonal failure must serum follicle stimulate hormone ( FSH ) level screen within postmenopausal range base Central Laboratory reference range Key A new AIDSdefining condition diagnose within 30 day prior screen Hepatitis B surface antigen position Hepatitis C antibody positive Participants experience decompensated cirrhosis Females breastfeed Positive serum pregnancy test Have implant defibrillator pacemaker Current alcohol substance use judge Investigator potentially interfere subject study compliance History malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior baseline Any clinical condition prior therapy , opinion Investigator , would make subject unsuitable study unable comply dose requirement Participation clinical trial without prior approval sponsor prohibit participate trial Participants receive ongoing therapy drug use elvitegravir ( EVG ) , COBI , FTC , TDF , ATV , RTV , EFV , TAF participant know allergy excipients E/C/F/TDF , E/C/F/TAF , EFV/FTC/TDF , ATV , COBI , RTV , FTC/TDF Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV 1 Infected</keyword>
	<keyword>Virologically-Suppressed</keyword>
</DOC>